News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Diana Kwon | May 29, 2018
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.
Immunotherapy More Effective in Men: Study
Kerry Grens | May 18, 2018
Women with metastatic cancer who were treated with a checkpoint inhibitor had a smaller benefit than did men.
FDA Approves Drug to Ease Symptoms of Opioid Withdrawal
Catherine Offord | May 17, 2018
Lucemyra is the first non-opioid drug to be approved in the U.S. specifically for this purpose.
Patient Registries to Bolster Cell- and Gene-Therapy Clinical Trial Data
Anna Azvolinsky | May 15, 2018
As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together real-world results.
Researchers Develop a Drug Against the Common Cold
Catherine Offord | May 15, 2018
In an in vitro study, the compound completely blocked the replication of rhinoviruses.
Research Scandal Involving Popular Heart Drug Engulfs Three More Papers
Alison McCook, Retraction Watch | May 4, 2018
The scientists involved have hired lawyers to fight the conclusions of a recent investigation into some studies of Diovan in Japan.
Staff | May 1, 2018
Take a break from the bench to puzzle and peruse.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Bioengineers Use Yeast to Manufacture Drugs
Jim Daley | Apr 3, 2018
The yeast’s output of noscapine, a cough suppressant naturally made by poppies, is 18,000-fold higher than previous attempts.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.